PriceTargets.com logo

Boston Scientific - BSX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $95.96
  • Forecasted Upside: 7.88%
  • Number of Analysts: 23
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 19 Buy Ratings
  • 1 Strong Buy Ratings
$88.95 As of 12/20/2024 06:31 PM ET
▲ +0.29 (0.33%)

This chart shows the closing price for BSX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Boston Scientific Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BSX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BSX

Analyst Price Target is $95.96
▲ +7.88% Upside Potential
This price target is based on 23 analysts offering 12 month price targets for Boston Scientific in the last 3 months. The average price target is $95.96, with a high forecast of $110.00 and a low forecast of $68.00. The average price target represents a 7.88% upside from the last price of $88.95.

This chart shows the closing price for BSX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 23 investment analysts is to moderate buy stock in Boston Scientific. This rating has held steady since March 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 13 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 1 strong buy ratings
  • 15 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 1 strong buy ratings
  • 16 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 1 strong buy ratings
  • 17 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 1 strong buy ratings
  • 19 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 1 strong buy ratings
  • 17 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 1 strong buy ratings
  • 19 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 1 strong buy ratings
  • 19 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 1 strong buy ratings
  • 19 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/18/2024Truist FinancialBoost TargetBuy ➝ Buy$100.00 ➝ $110.00
12/16/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$100.00 ➝ $110.00
12/12/2024TD CowenBoost TargetBuy ➝ Buy$100.00 ➝ $110.00
12/11/2024CitigroupBoost TargetBuy ➝ Buy$98.00 ➝ $107.00
12/11/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$98.00 ➝ $100.00
12/9/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$98.00 ➝ $101.00
11/27/2024Needham & Company LLCReiterated RatingHold
11/18/2024Needham & Company LLCReiterated RatingHold
10/31/2024Needham & Company LLCReiterated RatingHold
10/24/2024Sanford C. BernsteinBoost TargetOutperform ➝ Outperform$92.00 ➝ $100.00
10/24/2024Morgan StanleyBoost TargetOverweight ➝ Overweight$92.00 ➝ $100.00
10/24/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$95.00 ➝ $98.00
10/24/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$87.00 ➝ $98.00
10/24/2024CitigroupBoost TargetBuy ➝ Buy$92.00 ➝ $98.00
10/24/2024MizuhoBoost TargetOutperform ➝ Outperform$100.00 ➝ $110.00
10/24/2024Needham & Company LLCReiterated RatingHold
10/22/2024Bank of AmericaBoost TargetBuy ➝ Buy$90.00 ➝ $100.00
10/21/2024TD CowenBoost TargetBuy ➝ Buy$86.00 ➝ $100.00
10/21/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$88.00 ➝ $98.00
10/18/2024Stifel NicolausBoost TargetBuy ➝ Buy$85.00 ➝ $100.00
10/18/2024Needham & Company LLCDowngradeBuy ➝ Hold$86.00 ➝ $86.00
10/14/2024BTIG ResearchBoost TargetBuy ➝ Buy$84.00 ➝ $93.00
10/14/2024Truist FinancialBoost TargetBuy ➝ Buy$90.00 ➝ $100.00
10/8/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$85.00 ➝ $95.00
10/1/2024Evercore ISIBoost TargetOutperform ➝ Outperform$82.00 ➝ $90.00
9/4/2024Raymond JamesBoost TargetStrong-Buy ➝ Strong-Buy$91.00 ➝ $94.00
8/22/2024CitigroupBoost TargetBuy ➝ Buy$90.00 ➝ $92.00
8/22/2024BarclaysBoost TargetOverweight ➝ Overweight$78.00 ➝ $86.00
7/25/2024Deutsche Bank AktiengesellschaftBoost TargetHold ➝ Hold$73.00 ➝ $78.00
7/25/2024Raymond JamesBoost TargetStrong-Buy ➝ Strong-Buy$85.00 ➝ $91.00
7/25/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$85.00 ➝ $85.00
7/25/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$82.00 ➝ $85.00
7/25/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$83.00 ➝ $88.00
7/25/2024Needham & Company LLCBoost TargetBuy ➝ Buy$82.00 ➝ $86.00
7/25/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$90.00 ➝ $91.00
7/16/2024TD CowenBoost TargetBuy ➝ Buy$77.00 ➝ $86.00
7/16/2024Truist FinancialBoost TargetBuy ➝ Buy$86.00 ➝ $90.00
7/15/2024Morgan StanleyBoost TargetOverweight ➝ Overweight$79.00 ➝ $92.00
7/15/2024BTIG ResearchBoost TargetBuy ➝ Buy$80.00 ➝ $84.00
7/10/2024CitigroupBoost TargetBuy ➝ Buy$87.00 ➝ $90.00
7/2/2024Evercore ISIBoost TargetOutperform ➝ Outperform$78.00 ➝ $81.00
6/18/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$82.00 ➝ $82.00
5/30/2024The Goldman Sachs GroupInitiated CoverageBuy$90.00
5/28/2024ArgusBoost TargetBuy ➝ Buy$80.00 ➝ $95.00
5/22/2024CitigroupBoost TargetBuy ➝ Buy$85.00 ➝ $87.00
5/15/2024MizuhoBoost TargetBuy ➝ Buy$85.00 ➝ $90.00
4/26/2024BarclaysBoost TargetOverweight ➝ Overweight$70.00 ➝ $78.00
4/25/2024CitigroupBoost TargetBuy ➝ Buy$79.00 ➝ $85.00
4/25/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$72.00 ➝ $82.00
4/25/2024Deutsche Bank AktiengesellschaftBoost TargetHold ➝ Hold$63.00 ➝ $73.00
4/25/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$78.00 ➝ $82.00
4/25/2024Raymond JamesBoost TargetStrong-Buy ➝ Strong-Buy$73.00 ➝ $85.00
4/25/2024UBS GroupBoost TargetBuy ➝ Buy$74.00 ➝ $90.00
4/25/2024MizuhoBoost TargetBuy ➝ Buy$80.00 ➝ $85.00
4/25/2024Evercore ISIBoost TargetOutperform ➝ Outperform$72.00 ➝ $78.00
4/25/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$72.00 ➝ $82.00
4/25/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$79.00 ➝ $84.00
4/24/2024Needham & Company LLCBoost TargetBuy ➝ Buy$71.00 ➝ $82.00
4/15/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$70.00 ➝ $78.00
4/4/2024Evercore ISIBoost TargetOutperform ➝ Outperform$68.00 ➝ $72.00
4/3/2024CitigroupBoost TargetBuy ➝ Buy$71.00 ➝ $79.00
4/3/2024ArgusBoost TargetBuy ➝ Buy$69.00 ➝ $80.00
3/7/2024TD CowenBoost TargetOutperform ➝ Outperform$65.00 ➝ $77.00
2/1/2024CitigroupBoost TargetBuy ➝ Buy$65.00 ➝ $71.00
2/1/2024OppenheimerBoost TargetMarket Perform ➝ Market Perform$58.00 ➝ $68.00
2/1/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$67.00 ➝ $70.00
2/1/2024Raymond JamesBoost TargetStrong-Buy ➝ Strong-Buy$67.00 ➝ $73.00
2/1/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$60.00 ➝ $72.00
2/1/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$70.00 ➝ $72.00
2/1/2024MizuhoUpgradeNeutral ➝ Buy$65.00 ➝ $80.00
2/1/2024Needham & Company LLCBoost TargetBuy ➝ Buy$60.00 ➝ $71.00
1/16/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$67.00
1/3/2024Raymond JamesBoost TargetStrong-Buy ➝ Strong-Buy$61.00 ➝ $67.00
12/29/2023Wells Fargo & CompanyReiterated RatingOverweight ➝ Overweight$62.00
12/29/2023BTIG ResearchReiterated RatingBuy ➝ Buy$64.00
12/22/2023Truist FinancialBoost TargetBuy ➝ Buy$59.00 ➝ $66.00
12/13/2023Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$59.00 ➝ $62.00
12/12/2023TD CowenBoost TargetOutperform ➝ Outperform$58.00 ➝ $65.00
12/4/2023Morgan StanleyBoost TargetOverweight ➝ Overweight$58.00 ➝ $61.00
11/27/2023Canaccord Genuity GroupBoost TargetBuy ➝ Buy$60.00 ➝ $64.00
10/27/2023Needham & Company LLCLower TargetBuy ➝ Buy$65.00 ➝ $60.00
9/22/2023BarclaysBoost TargetOverweight ➝ Overweight$59.00 ➝ $60.00
9/21/2023Truist FinancialReiterated RatingBuy ➝ Buy$61.00
9/21/2023Canaccord Genuity GroupBoost TargetBuy ➝ Buy$62.00 ➝ $64.00
9/21/2023CitigroupReiterated RatingBuy ➝ Buy$63.00
9/21/2023BTIG ResearchBoost TargetBuy ➝ Buy$62.00 ➝ $64.00
9/21/2023Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$58.00 ➝ $61.00
9/21/2023UBS GroupBoost TargetBuy ➝ Buy$63.00 ➝ $66.00
9/21/2023Stifel NicolausBoost TargetBuy ➝ Buy$58.00 ➝ $60.00
9/21/2023Robert W. BairdBoost TargetOutperform ➝ Outperform$60.00 ➝ $63.00
9/21/2023MizuhoBoost TargetNeutral ➝ Neutral$56.00 ➝ $60.00
9/20/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$61.00
9/19/2023Evercore ISIReiterated RatingOutperform ➝ Outperform$60.00
9/11/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$61.00
8/28/2023CitigroupReiterated RatingBuy ➝ Buy$63.00
8/28/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$61.00
8/28/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$58.00
8/28/2023MizuhoReiterated RatingNeutral ➝ Neutral$56.00
8/11/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$61.00
7/31/2023BarclaysBoost TargetOverweight ➝ Overweight$56.00 ➝ $59.00
7/28/2023Canaccord Genuity GroupBoost TargetBuy$58.00 ➝ $62.00
7/28/2023Raymond JamesBoost Target$60.00 ➝ $61.00
7/28/2023Needham & Company LLCBoost TargetBuy$57.00 ➝ $61.00
7/28/2023OppenheimerBoost Target$58.00 ➝ $59.00
7/19/2023Truist FinancialBoost Target$60.00 ➝ $61.00
7/18/2023Robert W. BairdInitiated CoverageOutperform$59.00
7/17/2023BTIG ResearchBoost Target$56.00 ➝ $57.00
7/12/2023Royal Bank of CanadaBoost Target$56.00 ➝ $58.00
7/6/2023Piper SandlerBoost Target$58.00 ➝ $62.00
6/30/202322nd Century GroupReiterated RatingInitiates
6/30/2023CL KingInitiated CoverageBuy$64.00
5/30/2023Morgan StanleyInitiated CoverageOverweight$58.00
4/27/2023Stifel NicolausBoost Target$52.00 ➝ $58.00
4/27/2023Royal Bank of CanadaBoost Target$53.00 ➝ $56.00
4/27/2023Deutsche Bank AktiengesellschaftBoost Target$45.00 ➝ $55.00
4/27/2023BarclaysBoost Target$53.00 ➝ $56.00
4/18/2023MizuhoBoost Target$52.00 ➝ $56.00
4/17/2023Truist FinancialBoost TargetBuy$54.00 ➝ $59.00
4/17/2023BTIG ResearchBoost TargetBuy$53.00 ➝ $54.00
4/17/2023Raymond JamesBoost TargetStrong-Buy$56.00 ➝ $60.00
4/3/2023CitigroupBoost TargetBuy$54.00 ➝ $60.00
3/28/2023UBS GroupInitiated CoverageBuy$57.00
2/17/2023ArgusBoost Target$50.00 ➝ $55.00
2/2/2023JPMorgan Chase & Co.Boost TargetOverweight$48.00 ➝ $55.00
2/2/2023Needham & Company LLCBoost TargetBuy$48.00 ➝ $53.00
2/2/2023Raymond JamesBoost TargetStrong-Buy$54.00 ➝ $56.00
2/1/2023Stifel NicolausBoost Target$50.00 ➝ $52.00
1/6/2023Morgan StanleyBoost TargetOverweight$50.00 ➝ $56.00
1/4/2023BarclaysBoost Target$49.00 ➝ $53.00
12/22/2022MizuhoInitiated CoverageNeutral$52.00
12/20/2022Truist FinancialBoost TargetBuy$50.00 ➝ $54.00
12/20/2022CitigroupInitiated CoverageBuy$54.00
12/8/2022Raymond JamesBoost Target$48.00 ➝ $54.00
10/28/2022Canaccord Genuity GroupBoost TargetBuy ➝ Buy$45.00 ➝ $48.00
10/17/2022BarclaysInitiated CoverageOverweight$49.00
10/12/2022Jefferies Financial GroupInitiated CoverageBuy$50.00
10/11/2022Morgan StanleyBoost TargetOverweight$49.00 ➝ $50.00
9/9/2022Piper SandlerBoost TargetOverweight$47.00 ➝ $50.00
7/28/2022Canaccord Genuity GroupBoost Target$43.00 ➝ $45.00
7/28/2022BTIG ResearchBoost TargetBuy$45.00 ➝ $50.00
7/20/2022Truist FinancialLower TargetBuy$51.00 ➝ $45.00
7/15/2022Morgan StanleyLower TargetOverweight$51.00 ➝ $46.00
7/5/2022Wolfe ResearchInitiated CoverageOutperform$43.00
6/29/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$51.00 ➝ $43.00
6/24/2022BTIG ResearchLower TargetBuy$52.00 ➝ $45.00
5/27/2022Needham & Company LLCUpgradeHold ➝ Buy$48.00
5/24/2022BTIG ResearchReiterated RatingBuy$52.00
5/17/2022CitigroupLower TargetBuy$52.00 ➝ $47.00
4/13/2022Truist FinancialInitiated CoverageBuy$52.00
3/1/2022Bank of AmericaInitiated CoverageBuy ➝ Buy
2/3/2022Morgan StanleyLower TargetOverweight$53.00 ➝ $51.00
2/3/2022Raymond JamesLower TargetStrong-Buy$51.00 ➝ $49.00
2/3/2022Leerink PartnersLower TargetMarket Perform$48.00 ➝ $45.00
12/21/2021Truist FinancialBoost TargetBuy$52.00 ➝ $53.00
12/9/2021Royal Bank of CanadaInitiated CoverageOutperform$51.00
10/28/2021Raymond JamesLower TargetStrong-Buy$53.00 ➝ $51.00
9/21/2021Morgan StanleyReiterated RatingBuy$53.00
7/28/2021Credit Suisse GroupBoost TargetOutperform$50.00 ➝ $52.00
7/28/2021Raymond JamesBoost TargetStrong-Buy$50.00 ➝ $53.00
7/28/2021Morgan StanleyBoost TargetOverweight$51.00 ➝ $53.00
7/15/2021Needham & Company LLCSet TargetHold$42.74
6/7/2021ArgusBoost TargetBuy$45.00 ➝ $50.00
5/26/2021Needham & Company LLCDowngradeBuy ➝ Hold
5/24/2021BarclaysInitiated CoverageOverweight$51.00
4/29/2021Truist FinancialBoost Target$42.00 ➝ $50.00
4/29/2021Morgan StanleyBoost TargetOverweight$43.00 ➝ $51.00
4/29/2021Wells Fargo & CompanyBoost TargetIn-Line ➝ Overweight$42.00 ➝ $50.00
4/29/2021Deutsche Bank AktiengesellschaftBoost TargetHold$39.00 ➝ $45.00
4/15/2021Atlantic SecuritiesInitiated CoverageOverweight$52.00
2/12/2021Needham & Company LLCBoost TargetBuy$43.00 ➝ $46.00
2/4/2021Raymond JamesBoost TargetStrong-Buy$39.00 ➝ $43.00
2/3/2021Piper SandlerBoost TargetIn-Line ➝ Overweight$46.00 ➝ $48.00
2/1/2021Deutsche Bank AktiengesellschaftInitiated CoverageHold
12/15/2020Morgan StanleyBoost TargetOverweight$40.00 ➝ $43.00
12/15/2020The Goldman Sachs GroupDowngradeConviction-Buy ➝ Buy
12/8/2020BTIG ResearchReiterated RatingBuy
11/18/2020Truist FinancialLower Target$47.00 ➝ $44.00
11/18/2020Smith Barney CitigroupLower Target$46.00 ➝ $43.00
11/18/2020Wells Fargo & CompanyLower TargetOverweight$44.00 ➝ $41.00
11/18/2020Morgan StanleyLower TargetOverweight$41.00 ➝ $40.00
11/17/2020Needham & Company LLCLower TargetBuy$50.00 ➝ $43.00
10/29/2020Morgan StanleyLower TargetOverweight$48.00 ➝ $41.00
9/17/2020Truist FinancialInitiated CoverageBuy$47.00 ➝ $47.00
9/11/2020Wolfe ResearchInitiated CoverageMarket Perform$46.00
7/30/2020Stifel NicolausBoost TargetBuy$45.00 ➝ $47.00
7/30/2020Jefferies Financial GroupBoost TargetBuy$43.00 ➝ $46.00
7/30/2020CitigroupBoost TargetBuy$44.00 ➝ $46.00
7/30/2020Leerink PartnersBoost TargetMarket Perform$40.00 ➝ $43.00
7/30/2020Morgan StanleyBoost TargetOverweight$45.00 ➝ $48.00
7/29/2020Needham & Company LLCReiterated RatingBuy$50.00
7/29/2020OppenheimerBoost TargetMarket Perform$41.00 ➝ $43.00
6/24/2020Stifel NicolausReiterated RatingBuy$45.00
5/13/2020ArgusBoost TargetBuy$40.00 ➝ $42.00
4/30/2020CSFBBoost TargetOutperform$42.00 ➝ $43.00
4/30/2020Wells Fargo & CompanyBoost TargetOverweight$40.00 ➝ $41.00
4/30/2020Credit Suisse GroupBoost TargetOutperform$42.00 ➝ $43.00
4/30/2020CitigroupBoost TargetBuy$40.00 ➝ $42.00
4/30/2020UBS GroupLower TargetBuy$50.00 ➝ $45.00
4/30/2020Stifel NicolausBoost TargetBuy$35.00 ➝ $45.00
4/30/2020Raymond JamesBoost TargetStrong-Buy$42.00 ➝ $43.00
4/30/2020OppenheimerReiterated RatingHold$46.00 ➝ $41.00
4/29/2020BTIG ResearchReiterated RatingBuy$44.00
4/29/2020Needham & Company LLCReiterated RatingBuy$46.00
4/23/2020SunTrust BanksLower TargetBuy$28.00 ➝ $25.00
4/22/2020Leerink PartnersDowngradeOutperform ➝ Market Perform$40.00
4/9/2020Raymond JamesLower TargetStrong-Buy$49.00 ➝ $42.00
4/2/2020Piper SandlerReiterated RatingBuy
4/2/2020Needham & Company LLCLower TargetBuy$53.00 ➝ $43.00
4/1/2020The Goldman Sachs GroupUpgradeNeutral ➝ Conviction-Buy$46.00 ➝ $38.00
3/27/2020CitigroupLower TargetBuy$48.00 ➝ $40.00
3/24/2020Stifel NicolausLower TargetBuy$47.00 ➝ $30.00
3/23/2020StephensLower TargetOverweight$48.00 ➝ $35.00
3/9/2020CfraUpgradeBuy ➝ Strong-Buy$50.00 ➝ $47.00
3/6/2020Credit Suisse GroupLower TargetOutperform$51.00 ➝ $46.00
3/4/2020CitigroupInitiated CoverageBuy$48.00
2/12/2020The Goldman Sachs GroupInitiated CoverageNeutral$46.00
2/6/2020BTIG ResearchInitiated CoverageBuy$46.00
1/15/2020CowenReiterated RatingBuy$52.00
1/14/2020Piper SandlerReiterated RatingBuy
12/30/2019CowenBoost TargetOutperform$47.00 ➝ $52.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.23 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 43 very positive mentions
  • 46 positive mentions
  • 4 negative mentions
  • 7 very negative mentions
Mentions as of
5/24/2024
  • 38 very positive mentions
  • 23 positive mentions
  • 8 negative mentions
  • 1 very negative mentions
Mentions as of
6/23/2024
  • 25 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
7/23/2024
  • 32 very positive mentions
  • 40 positive mentions
  • 4 negative mentions
  • 7 very negative mentions
Mentions as of
8/22/2024
  • 36 very positive mentions
  • 27 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 35 very positive mentions
  • 32 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
Mentions as of
10/21/2024
  • 61 very positive mentions
  • 46 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024
  • 83 very positive mentions
  • 30 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
12/20/2024

Current Sentiment

  • 83 very positive mentions
  • 30 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Boston Scientific logo
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Read More

Today's Range

Now: $88.95
Low: $87.25
High: $89.67

50 Day Range

MA: $88.31
Low: $83.62
High: $91.54

52 Week Range

Now: $88.95
Low: $54.96
High: $91.93

Volume

15,881,501 shs

Average Volume

6,000,576 shs

Market Capitalization

$131.10 billion

P/E Ratio

73.51

Dividend Yield

N/A

Beta

0.8

Frequently Asked Questions

What sell-side analysts currently cover shares of Boston Scientific?

The following Wall Street analysts have issued reports on Boston Scientific in the last twelve months: Argus, Bank of America Co., Barclays PLC, BTIG Research, Canaccord Genuity Group Inc., Citigroup Inc., Deutsche Bank Aktiengesellschaft, Evercore ISI, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Raymond James, Robert W. Baird, Royal Bank of Canada, Sanford C. Bernstein, Stifel Nicolaus, StockNews.com, TD Cowen, The Goldman Sachs Group, Inc., Truist Financial Co., UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for BSX.

What is the current price target for Boston Scientific?

0 Wall Street analysts have set twelve-month price targets for Boston Scientific in the last year. Their average twelve-month price target is $95.96, suggesting a possible upside of 7.9%. JPMorgan Chase & Co. has the highest price target set, predicting BSX will reach $110.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $68.00 for Boston Scientific in the next year.
View the latest price targets for BSX.

What is the current consensus analyst rating for Boston Scientific?

Boston Scientific currently has 3 hold ratings, 19 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for BSX.

What other companies compete with Boston Scientific?

Other companies that are similar to Boston Scientific include Abbott Laboratories, Intuitive Surgical, Stryker, Medtronic and Becton, Dickinson and Company. Learn More about companies similar to Boston Scientific.

How do I contact Boston Scientific's investor relations team?

Boston Scientific's physical mailing address is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. The medical equipment provider's listed phone number is (508) 683-4000 and its investor relations email address is [email protected]. The official website for Boston Scientific is www.bostonscientific.com. Learn More about contacing Boston Scientific investor relations.